• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

Gilead, Tentarix Strike $66M Oncology and Inflammatory Therapy Deal


Partnership aims to enhance therapeutic benefit and safety.

High-tech modern CT scan room in the modern hospital. Image Credit: Adobe Stock Images/didiksaputra

Image Credit: Adobe Stock Images/didiksaputra

Gilead Sciences and Tentarix Biotherapeutics have officially started three multi-year collaborations with the goal of discovering and developing multi-functional, conditional protein therapeutics for oncology and inflammatory diseases. Intended to improve therapeutic benefit and safety, the companies believe these molecules could conditionally target immune cells related to disease pathways without activating other immune cells that may create hostile events.

“At Gilead, a key area of our research strategy is addressing immune dysregulation in oncology and inflammatory diseases,” said Flavius Martin, MD, EVP, research, Gilead Sciences, in a company press release. “This early-stage collaboration with Tentarix will be highly synergistic to our ongoing efforts, building upon our growing strength in protein therapeutics, and may provide access to next-generation, multi-specific biologics.”

Reference: Gilead and Tentarix to Discover and Develop Novel Therapies to Address Unmet Medical Needs Across Cancer and Inflammation. Gilead. August 15, 2023. Accessed August 17, 2023. https://www.gilead.com/news-and-press/press-room/press-releases/2023/8/gilead-and-tentarix-to-discover-and-develop-novel-therapies-to-address-unmet-medical-needs-across-cancer-and-inflammation

Recent Videos
Related Content